Blogs Calcitonin Receptor (CTR): Biological Functions, Disease Relevance, and Drug Discovery Applications

Calcitonin Receptor (CTR): Biological Functions, Disease Relevance, and Drug Discovery Applications

The calcitonin receptor (CTR) is a class B (GPCR) involved in calcium homeostasis, bone metabolism, and peptide hormone signaling. Encoded by the CALCR gene, CTR is primarily activated by calcitonin, a peptide hormone secreted by the thyroid gland that helps regulate calcium levels by inhibiting bone resorption.

CTR Blog Image (1)

CTR is expressed in several tissues, including bone, kidney, and regions of the central nervous system. Upon activation, the receptor primarily signals through Gs proteins, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP).

Beyond its established role in skeletal physiology, CTR has gained attention in drug discovery because of its relationship with the amylin receptor family. These receptors share a common molecular component but exhibit distinct pharmacological properties, making CTR an important target for researchers developing peptide therapeutics, including compounds intended to activate multiple receptors involved in metabolic regulation.

Biological Functions of the Calcitonin Receptor (CTR)

CTR participates in several physiological processes, including:

  • Bone remodeling: CTR activation inhibits osteoclast activity, reducing bone resorption and the release of calcium from bone into circulation.
  • Calcium regulation: Calcitonin signaling contributes to calcium homeostasis, particularly when bone resorption is elevated.
  • Renal function: Calcitonin influences renal calcium and phosphate handling, contributing to mineral balance.
  • Peptide hormone signaling: CTR interacts with receptor activity-modifying proteins (RAMPs), altering ligand recognition and enabling responses to additional peptide hormones, including amylin.

While parathyroid hormone and vitamin D are the primary regulators of calcium homeostasis, calcitonin receptor activation plays a role in suppressing osteoclast activity, making CTR a target for studying bone resorption and related disorders.

The Calcitonin Receptor's Role in Disease

CTR signaling has implications for several diseases and therapeutic research areas.

Osteoporosis: Osteoporosis is characterized by reduced bone mass and increased fracture risk. Because CTR activation suppresses osteoclast-mediated bone resorption, calcitonin-based therapies have historically been used to treat osteoporosis. However, their clinical use has become limited due to comparatively modest efficacy and safety considerations.

Paget's Disease of Bone: Paget's disease involves excessive and disorganized bone remodeling. Calcitonin receptor agonists can reduce osteoclast activity and bone turnover, although bisphosphonates are generally preferred for treatment.

Hypercalcemia: Elevated blood calcium levels can occur in conditions associated with increased bone resorption, including certain malignancies. Calcitonin can rapidly lower serum calcium through CTR activation, making it useful for short-term management of severe hypercalcemia.

Metabolic Disease and Obesity: CTR also contributes to the pharmacology of amylin receptors, which are involved in appetite regulation, gastric emptying, and glucose homeostasis. This relationship has generated interest in the pharmacology of CTR and related receptors as researchers investigate amylin-based and dual-acting peptide therapeutics for obesity and metabolic disorders.

How Is CTR Related to Amylin Receptors (AMY1–3)?

One important feature of CTR pharmacology is its relationship with the three amylin receptors: AMY1, AMY2, and AMY3.

Unlike many GPCR families, these receptors are not encoded by three separate receptor genes. Instead, they are formed when CTR associates with different receptor activity-modifying proteins:

  • AMY1: CTR combined with RAMP1
  • AMY2: CTR combined with RAMP2
  • AMY3: CTR combined with RAMP3

These interactions alter receptor pharmacology, particularly ligand recognition and responsiveness. While CTR alone preferentially responds to calcitonin, the AMY1–3 receptor complexes generally exhibit greater sensitivity to amylin.

Although CTR and the amylin receptors exhibit distinct pharmacological preferences, ligand selectivity is not absolute. Certain peptides, including salmon calcitonin and dual-acting receptor agonists, can activate multiple members of the receptor family. The potency and efficacy of these responses may also vary depending on CTR splice variants, RAMP composition, and cellular background.

These overlapping pharmacological properties make comparative receptor testing particularly important. Evaluating compounds across CTR and related amylin receptors helps researchers distinguish receptor-selective activity from broader agonist profiles and characterize candidates designed to activate multiple receptors.

Dual Amylin and Calcitonin Receptor Agonists in Metabolic Drug Discovery

An emerging area of CTR research involves dual amylin and calcitonin receptor agonists (DACRAs), a class of peptide therapeutics being investigated for obesity and metabolic disorders.

These compounds are designed to activate both CTR and amylin receptors. Because individual compounds can exhibit different potency and efficacy profiles across CTR, AMY1, AMY2, and AMY3 receptors, understanding their functional activity at each target is important for characterizing compound pharmacology.

Research involving long-acting amylin analogs, including cagrilintide, has further highlighted the importance of understanding ligand interactions with CTR and the amylin receptor family. Structural and pharmacological studies have demonstrated that peptide ligands can engage these related receptors through distinct molecular interactions, contributing to differences in receptor activation and signaling responses.

For researchers developing these therapeutics, functional receptor assays provide a means of evaluating concentration-dependent responses, comparing receptor activity profiles, and characterizing the pharmacological properties of candidate compounds. These data can support the selection and further development of peptide therapeutics with defined receptor activity profiles.

The Calcitonin Receptor in Drug Discovery

CTR remains a relevant therapeutic target, particularly as interest grows in peptide-based medicines and metabolic disease treatments.

Research involving CTR and related amylin receptors supports several areas of drug development:

  • Agonist discovery: Identifying compounds capable of activating CTR and characterizing their potency and efficacy.
  • Receptor selectivity: Comparing compound activity across CTR and AMY1–3 receptors to distinguish selective from broader pharmacological profiles.
  • Peptide therapeutic development: Evaluating calcitonin analogs, amylin analogs, and other peptide candidates with overlapping receptor activity.
  • Metabolic drug discovery: Investigating receptor pharmacology relevant to appetite regulation, glucose homeostasis, and obesity therapeutics.

Cell-based reporter assays provide a functional approach to evaluating CTR activation. By measuring reporter gene expression in response to receptor signaling, researchers can generate concentration-response curves, determine EC50 values, and compare the relative efficacy of candidate compounds. Unlike receptor binding measurements, these assays provide information about the functional response produced following receptor activation.

This distinction is particularly relevant when investigating peptides with overlapping activity across CTR and amylin receptors. Evaluating functional responses across related receptor targets can help researchers characterize differences in agonist potency, efficacy, and receptor selectivity, providing additional information for compound prioritization.

INDIGO’s Human CTR Reporter Assay

INDIGO Biosciences' Human Calcitonin Receptor (CTR) Reporter Assay provides researchers with a convenient cell-based platform for evaluating functional receptor activity.

Using , the assay enables researchers to quantify receptor activation and characterize concentration-dependent responses to candidate compounds. Applications include agonist screening, potency and efficacy characterization, and comparative pharmacological studies involving calcitonin analogs and other peptide therapeutics.

INDIGO also offers Human AMY1R Reporter Assays and Human AMY3R Reporter Assays, providing additional options for researchers investigating the functional activity of related peptide receptors.

Together, these assays support the characterization of receptor activity profiles across CTR, AMY1R, and AMY3R. This approach is particularly relevant for researchers developing amylin-based therapeutics and dual amylin and calcitonin receptor agonists, where differences in receptor selectivity, potency, and efficacy can influence compound development strategies.

Explore INDIGO Biosciences' Human Calcitonin Receptor Reporter Assay to learn how functional receptor testing can support your drug discovery program, or contact INDIGO to discuss your research needs.

References

Alexander, S. P. H. et al. (2025). The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors. British Journal of Pharmacology, 182(S1), S24-S151. https://doi.org/10.1111/bph.70230

Garelja ML, Hay DL. (2022). A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond. Headache, 62: 1093-1104. doi: 10.1111/head.14388

Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018). Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. British journal of pharmacology, 175(1), 3–17. https://doi.org/10.1111/bph.14075